BridgeBio shares slip as 2031 drug pricing risk pops up
BridgeBio Pharma shares fell 2.8% to $67.18 after Raymond James downgraded the stock, citing payer-driven risks for its heart drug Attruby. The downgrade follows concerns that insurers may favor cheaper generics as Pfizer’s Vyndamax nears loss of exclusivity in 2031. BridgeBio reported $194.5 million in Q1 revenue, mostly from Attruby, and approved a $500 million buyback. The stock lagged biotech sector gains Tuesday.
